| Name | Relationship | Address | Signature | Signature date | CIK |
|---|---|---|---|---|---|
| Schoenherr Thomas Edward | CEO, Diagnostics | C/O TEMPUS AI, INC., 600 WEST CHICAGO AVENUE, SUITE 510, CHICAGO | /s/ Andrew Polovin, Attorney-in-Fact | 25 Feb 2026 | 0002113721 |
| Type | Sym | Class | Transaction | Value $ | Shares | Change % | * Price $ | Shares After | Date | Ownership | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|
| holding | TEM | Class A Common Stock | 94,967 | 20 Feb 2026 | Direct | F1 |
| Id | Content |
|---|---|
| F1 | Includes (i) 54,405 restricted stock units ("RSUs"), of which 27,180 RSUs vest on each of February 15, 2027 and February 15, 2028 and 15 RSUs vest on each of April 15, 2026, July 15, 2026 and October 15, 2026, and (ii) 20,000 shares certified as earned with respect to an award of performance-based stock units ("PSUs") granted on August 7, 2025. The Issuer's Board of Directors certified the achievement of the applicable performance metrics and goals on February 20, 2026 and the PSUs will vest, in accordance with their terms, on August 15, 2026. |